One of the main issues the Foundation focuses on is antimicrobial resistance (AMR), which disproportionately affects the most vulnerable populations, including people living in low- and middle-income countries. The Antimicrobial Resistance programme (AMR programme) will guide and incentivise pharmaceutical companies to do more to address the issue of AMR. The AMR Benchmark, for example, will measure and assess the efforts of pharmaceutical companies (from research-based companies to generic medicines manufacturers) in several research areas, including R&D, appropriate access, stewardship, and responsible manufacturing.
Quality research and analysis are essential activities within the Access to Medicine Foundation to achieve these change making goals. As a researcher you should be proactive, solution-oriented, motivated, curious, flexible, and would like to contribute to advancing the research activities at the Foundation. In this role, you will excel as a team player who collaborates and communicates clearly about our research. This research will focus on ensuring continuous supply of antimicrobials in low- and middle-income countries and the responsible manufacturing practices of companies to limit the release of antibiotic waste into the environment.

What does the role look like

• Drive the analysis underpinning specific thematic areas of the Antimicrobial Resistance Benchmark or any thematic study, including comparative company analysis and industry-wide trends;
  
• Research and analyse efforts by pharmaceutical companies on specific topics such as continuous supply of antimicrobials, prevention of shortages and stockouts, responsible manufacturing across supply chains and antibacterial waste management;
  
• Evaluate company performance in antimicrobial resistance by analysing quality-controlled data obtained from the public domain and collected from companies directly;
  
• Engage with external stakeholders as needed to develop the methodology for the Antimicrobial Resistance Benchmark or any thematic study. This includes identifying, analysing, and presenting trends in the specific thematic areas of antimicrobial resistance defined in the Benchmark;
  
• Collaborate efficiently with other staff members in the research team(s) and those in charge of management, communications, operations and data management and engage with company representatives, as needed;
  

What we are looking for

• Individuals with a master’s degree in a clinical/biomedical sciences, pharmaceutical sciences or a pharmacy (Pharm D) or medical degree;
  
• Experience and background in related disciplines such global health, health policy, sustainability, microbiology, supply chain management, is a plus;
  
• Knowledge of health products and/or drug development and regulatory approval processes;
  
• Experience working with or within the innovative pharmaceutical, generic medicine, diagnostics or medical device industry (especially in the context of low- and middle-income countries) is a plus;
  
• Keen interest or experience working with global health issues;
  
• Excellent critical thinker with solid qualitative and quantitative analytical skills. Able to identify relevant trends in large data sets, to present data accurately and concisely with a sharp eye for detail and, to explain conclusions clearly.
  
• Advanced skills in Excel (and Office 365 in general). Experience with Airtable, is a plus;
  
• Strong time management skills and the ability to set priorities to achieve multiple projects and deadlines, and to identify risks and opportunities and escalate these when appropriate in a timely manner to the line manager(s);
  
• Active communicators with excellent command of English, both spoken and written (academic and media styles).
  
• The positions will be based in Amsterdam and a valid work permit to work in the Netherlands is needed, EU applicants are welcome.
  

What we offer you

• A dynamic, innovative, working environment with an international team based in our Amsterdam office;
  
• Hybrid options available: 2-3 days per week in our office in Amsterdam, with the option to work from your home in the Netherlands on the remaining days. (This position is not available for remote working in a country outside the Netherlands – there will be no compensation for relocation costs);
  
• Being part of the development of analyses, reports, and material for events;
  
• The possibility to work in a team where you can learn from each other;
  
• Benefits include 25 holidays on an annual basis based on a full-time employment, mandatory company pension scheme, holiday allowance and reimbursement of public transport to work (if living beyond 10km from the office).
  

More about the Antimicrobial Resistance Programme

The Antimicrobial Resistance Benchmark (AMR Benchmark) is the first independent analysis of pharmaceutical industry efforts to tackle drug resistance and ensure appropriate access to their products in low- and middle-income countries. It compares how a cross-section of the pharmaceutical companies is responding to the threat of drug-resistant infections.
It measures the most active players in the antimicrobial space and includes large research-based companies, manufacturers of generic medicines and small- and medium-sized enterprises (SMEs). The main areas tracked are R&D for new antimicrobials, strategies for ensuring antibiotics are manufactured responsibly, and approaches to ensure antimicrobials are accessible in low- and middle-income countries and used appropriately.

How to apply

Interested in this exciting opportunity? Please send the following documents to Mrs. Mireille Deen at recruitment@accesstomedicinefoundation.org:

• a cover letter with your motivation on why you would like to join the Access to Medicine Foundation and how you think you will fit in our team;
  
• your resume;
  
• one writing sample (i.e. published article, thesis or white paper)
  
• the contact details of two references (e-mail address and/or phone number);
  

The application will not be considered unless it is complete, and all supporting documentation has been provided. There will be no compensation for relocation costs.